HOME >> MEDICINE >> NEWS
St. John's wort ineffective for depression

DURHAM, N.C. The largest clinical trial performed to date on the popular herbal supplement St. John's wort (Hypericum perforatum) has found it to be no more effective than placebo for the treatment of a moderately severe form of major depression, according to researchers at Duke University Medical Center. Major depression, also called major depressive disorder, is one of the most common forms of depression.

Researchers designed the study to test the efficacy of St. John's wort (SJW) versus placebo for the treatment of major depression. In their study, they used the antidepressant sertraline (trade name Zoloft), which is a selective serotonin reuptake inhibitor (SSRI), as a "control" to measure the sensitivity of the study for detecting antidepressant effects of hypericum. SSRIs such as sertraline are a class of drug found to be effective in treating several forms of depression.

"Major depression is treatable, but this research suggests that major depression of at least moderate severity should not be treated with St. John's wort," said Jonathan R.T. Davidson, M.D., director of the Anxiety and Traumatic Stress Program at Duke and principal investigator of the study. "Rather than self-medicate with an over-the-counter medication or supplement, patients are strongly advised to consult an appropriate healthcare provider to assess the best treatment for a depressive episode."

Another author on the study, Robert Califf, M.D., director of the Duke Clinical Research Institute, emphasized the dangers of inadequate studies of St. John's wort and other herbal remedies.

"As long as these types of products remain available to the public without the protection of adequate, controlled and unbiased studies, taking them is like playing Russian roulette with your health," he said.

Study results appear in the April 10, 2002 issue of the Journal of the American Medical Association. Duke University Medical Center, Duke Clinical Research Institute (DCRI)
'"/>

Contact: Tracey Koepke
koepk002@mc.duke.edu
919-684-4148
Duke University
9-Apr-2002


Page: 1 2 3 4 5

Related medicine news :

1. St. Johns wort amplifies effect of blood thinner Plavix
2. The effects of St. Johns Wort (Hypericum perforatum)
3. UT Southwestern Study To Test Efficacy Of St. Johns Wort For Treatment Of Depression
4. Study Finds St. Johns Wort Can Cut Alcohol Consumption
5. Government wasting your taxpayer money on ineffective drug cure
6. School-based smoking prevention programs ineffective
7. Surgical procedure to treat GERD in children found to be ineffective
8. Fetal heart monitoring ineffective at diagnosing cerebral palsy
9. Doubling of steroid before severe asthma attack ineffective
10. Promising drug proves ineffective as treatment for hearing loss
11. Screening children for speech problems is ineffective

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: John wort ineffective for depression

(Date:7/31/2014)... Women over the age of 65 face numerous barriers ... struggles against poverty and higher rates of asthma with ... issue of Annals of Allergy, Asthma and Immunology ... Allergy, Asthma and Immunology (ACAAI), outlines the challenges faced ... solutions to improve their care. , "Allergists ...
(Date:7/31/2014)... 2014 The 2013 PolyU TSI ... points from 75.07 in 2012. The index measures ... and integrates them into an overall index. The ... more satisfied with Hong Kong over time. , ... in service performance in Hong Kong are attractions ...
(Date:7/31/2014)... 2014 Ce-Classes.com has announced that they ... healthcare professionals, a Systematic Review of Sexual Satisfaction ... in the International Journal of Clinical and Health Psychology. ... to a need to have accurate information about sexual ... treatment possible. The material provides a systematic review ...
(Date:7/31/2014)... GA (PRWEB) July 31, 2014 In today’s ... increasingly difficult to get. Snoring and sleep apnea (a medical ... rob people and their bed partners of the rest they ... 45% of the population snores and 20 million people in ... 10% have been diagnosed and treated; and of those treated, ...
(Date:7/31/2014)... Weblify has finally been released by marketing and advertising ... The result is a perfected and fine tuned platform ... minutes without knowing any HTML or other programming languages. , ... SEO expert, agrees that this platform allows anyone to create ... web site builders out there, but this is truly unique. ...
Breaking Medicine News(10 mins):Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 3
(Date:7/31/2014)... , July 31, 2014 Catylix, Inc. ... Scientific ( Milpitas, California ) announced ... develop and commercialize new fluorination products and related ... has benefited from the use of substituents that ... lipophilicity with polarity to improve binding and bioavailability. ...
(Date:7/31/2014)... the list of stocks featured in the Analyst Blog. Every ... and events impacting stocks and the financial markets. Stocks recently ... Free Report ), Gilead (Nasdaq: GILD - Free Report ... AbbVie (NYSE: ABBV - Free Report ) and Celgene ... Zacks is promoting its ,Buy, stock recommendations. Get #1Stock ...
(Date:7/31/2014)... Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company ... conference call on Thursday, August 14, 2014, at 4:30 p.m. ... June 30, 2014. Financial results will be issued in a ... President and CEO James LaFrance will host the ... Date: Thursday, August 14, 2014 Time: 4:30 p.m. Eastern time ...
Breaking Medicine Technology:Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
Cached News: